Literature DB >> 17574937

Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection.

Arianna Loregian1, Maria Cristina Scarpa, Silvana Pagni, Saverio Giuseppe Parisi, Giorgio Palù.   

Abstract

A simple high-performance liquid chromatography method for the determination of the antiviral agent ribavirin in human plasma was developed and validated. The method involved solid-phase extraction on phenyl boronic acid cartridges, a reversed-phase liquid chromatography with a Waters Atlantis dC18 (150 mm x 3.9 mm, 5 microm) column and a mobile phase consisting of 10 mM potassium phosphate buffer (pH 4.0), and ultraviolet detection at 207 nm. This assay proved to be sensitive (lower limit of quantification of 0.05 microg/ml), linear (correlation coefficients >or=0.997), specific (no interference with various potentially co-administrated drugs), reproducible (both intra-day and inter-day coefficients of variation <or=4.3%), and accurate (deviations ranged from -5.6 to 2.2% and from -6.0 to 4.0% for intra-day and inter-day analysis, respectively). The method was applied to therapeutic monitoring of patients undergoing ribavirin treatment for hepatitis C and proved to be robust and reliable. Thus, this method provides a simple, sensitive, precise and reproducible assay for dosing ribavirin that can be readily adaptable to routine use by clinical laboratories with standard equipment. In addition, we evaluated the stability of ribavirin in plasma under various conditions, since no detailed study on thermal stability of ribavirin has been reported so far and discrepant data do exist on ribavirin stability upon conditions that clinical samples commonly experience. Ribavirin was stable in human plasma stored at room temperature for at least 24 h or at -20 degrees C for up to 1 month, after three freeze-thaw cycles, as well as in samples undergoing heat inactivation of infectious viruses for 60 min at 60 degrees C. The drug was also stable in processed samples stored at -20 degrees C for 3 days (as dried extracts) or at 20 degrees C for 4 days (as reconstituted samples).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574937     DOI: 10.1016/j.jchromb.2007.05.039

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  The investigation of the interaction between ribavirin and bovine serum albumin by spectroscopic methods.

Authors:  Xing-Jia Guo; Ai-Jun Hao; Xiao-Wei Han; Ping-Li Kang; Yu-Chun Jiang; Xiang-Jun Zhang
Journal:  Mol Biol Rep       Date:  2010-12-03       Impact factor: 2.316

2.  Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry.

Authors:  Leah C Jimmerson; Jia-Hua Zheng; Lane R Bushman; Christine E MacBrayne; Peter L Anderson; Jennifer J Kiser
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-10-31       Impact factor: 3.205

3.  Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay.

Authors:  Emilie Fromentin; Ghazia Asif; Aleksandr Obikhod; Selwyn J Hurwitz; Raymond F Schinazi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-27       Impact factor: 3.205

4.  Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.

Authors:  Francois-Ludovic Sauvage; Francoise Stanke-Labesque; Marie-Claude Gagnieu; Jean-Francois Jourdil; Gerard Babany; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

5.  Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria.

Authors:  Cyril Erameh; Osahogie Edeawe; Peter Akhideno; Gloria Eifediyi; Till F Omansen; Christine Wagner; Francisca Sarpong; Till Koch; Sebastian Wicha; Florian Kurth; Sophie Duraffour; Lisa Oestereich; Meike Pahlmann; Sylvanus Okogbenin; Ephraim Ogbaini-Emovon; Stephan Günther; Michael Ramharter; Mirjam Groger
Journal:  BMJ Open       Date:  2020-04-16       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.